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The Psychosocial Effects of Next Generation Sequence Panels for Predictive Testing of 
Hereditary Dementias 
Dina Green 
Abstract 
 
The current standard of care in offering predictive genetic testing for neurodegenerative 
diseases is that individuals wishing to have testing must have a known family mutation or 
well-documented family history of a specific disease. This model denies testing to 
individuals in families where the phenotype of the disease is less clear. However, NGS panel 
testing for many genes with overlapping phenotypes helps alleviate both the cost and tedious 
nature of a genetic “fishing expedition.” Panel testing increases the risk of receiving variants 
of unknown significance and, therefore, uncertainty. The goal of this research study is to 
examine the psychological impact of predictive testing of neurodegenerative disease using 
NGS panels. Methods: This pilot study looked at 15 at-risk participants with a family 
mutation and 8 without a known family mutation. Participants were evaluated serially: before 
testing, at 1 month and at 6 months after receiving results.   Instruments measuring levels of 
anxiety, depression, ability to deal with uncertainty, coping strategies, perceived personal 
control, and rumination were used to evaluate the psychological impact of testing on the 2 
groups.  Results: No significant differences were found between the two groups. A noted 
trend was an increase in uncertainty after testing among those with a known mutation and a 
small decrease among those without a known mutation. Statistical significance was not 
observed due to small number of participants. Initial data suggest that predictive testing for 
neurodegenerative disease in individuals with a family history does not result in 
psychological distress.  The study is ongoing. 
Key Words: Genetic Counseling, adult neurogenetics, dementia, predictive testing, 
asymptomatic 
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Introduction 
 
The current standard of care for predictive genetic testing for neurodegenerative 
diseases requires that healthy individuals seeking testing must have a known family mutation 
or well-documented family history of a specific disease, preferably one that includes autopsy 
results. This standard means that upon testing a definitive answer can be obtained for the 
patient. If, however, the phenotype of the disease running in the family is less clear, a series 
of genetic tests may be necessary to rule out related diseases. (Goldman, 2012) In this case, 
there is a higher likelihood of receiving both variants of unknown significance (VUS) and 
false negatives. Panel testing for many genes with overlapping phenotypes can help alleviate 
both the cost and the tedious nature of a genetic ’fishing expedition’. The limitations to panel 
testing include the inability to detect repeat disorder and in some labs, duplications, and 
deletions. (Beck, 2014) 
The chance of receiving a VUS increases with the number of genes tested. Many 
times, the affected family member cannot be tested to identify a mutation, which can leave an 
at-risk patient who wants testing with limited options. The rise of panel testing and the 
existence of a proven protocol for the testing of single-gene disorders such as Huntington’s 
disease (HD) raises questions about whether it is still ethical to deny these patients testing. 
The HD protocol provides a theoretical framework that could serve to help the patient cope 
with the consequences of testing for severe neurodegenerative disorders when there are no 
known treatments. A similar protocol could be applied to panel testing and provide informed 
consent to patients, including information on potential results. There is currently an absence 
of research examining the use of panels for predictive testing for neurodegenerative diseases.  
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The HD Protocol as a Model 
Due to the life-altering nature and psycho-social implications of testing results, 
testing for HD includes a multi-step process which is highly recommended for all patients. 
HD is a progressive neurodegenerative disease with the average onset occurring in the 30-
50’s. The disease typically begins with a movement disorder and psychiatric symptoms and 
progresses into dementia and severe neurodegeneration. The disease is caused by a 
trinucleotide repeat in the HTT gene. The expansion is inherited in an autosomal dominant 
manner and is nearly fully penetrant. Therefore, genetic testing is predictive to a degree that 
is rare amongst hereditary dementias.  
Guidelines for HD testing were first established in 1994 and were updated in 2013. 
(MacLeod, et al.) The process includes: genetic counseling, a psychiatric evaluation, a 
neurological evaluation, and post-results counseling. The patient is asked to bring a support 
person to the initial genetic counseling consultation and to the results session. The goal of the 
process is to ensure that those seeking testing are psychologically equipped to handle the 
result, that they are informed, and that they have appropriate reasons for testing (i.e. have a 
relevant family history). Those seeking testing are given the tools to contemplate the 
ramifications of testing, including the potential implications for loved ones. Anxiety can be 
present in all cases, even when a negative result is received. (Williams , Erwin, & Juhl, 2010) 
Some patients from HD families have been shown to experience “survivor’s guilt” upon 
receiving a negative test result. (Hayden & Bombard, 2005) The protocol has largely been 
found to be successful. (Almqvist, et al., 2003; Dufranse, et al., 2011; Timman, et al., 2004) 
The HD protocol is recommended for presymptomatic testing for other neurodegenerative 
diseases as well. A past history of depression or anxiety may signal the need for additional 
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counseling or referral to a mental health professional. (Reichelt, et al., 2004) It is considered 
essential for patients seeking presymtomatic testing for conditions such as Alzheimer’s 
disease (AD) and Frontotemporal Degradation (FTD) to receive formal counseling, time and 
support when making the decision to test. (Loy, et al.,2013)  
Testing for Hereditary Dementias 
Recent gene discoveries and advances in technology are contributing to rapid changes 
in genetic testing for dementias. The present state of testing is complicated by the variability 
and overlapping expression of diseases. Genetic testing has the ability to accurately predict a 
patient’s lifetime risk for HD and a limited number of other neurological conditions. This 
accuracy is rarely available for the majority of dementias. AD and FTD are two of the most 
common dementias. Each is a prime example of variable and overlapping expressivity with 
regard to other dementias, and for each condition multiple genes may be implicated by the 
phenotype.  
PSEN1, PSEN2, and APP are the only known autosomal dominant AD genes 
(Goldman, 2012).  It is rare that insurance will cover diagnostic testing for dementias and it is 
even more uncommon that they will cover the cost for predictive testing. (Goldman, 2012; 
Green and Botkin, 2003) These three genes exist as a panel at a cost of range of several 
thousand to several hundred dollars. The price then increases with any additional reflex 
testing. Furthermore, a number of other factors must be considered before testing, including 
the effect testing will have on other family members, the proband’s capacity to consent, and 
the effect of testing on insurance for unaffected individuals.  
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A detailed family history spanning three generations is required prior to testing. 
(Goldman, 2012; Loy, et al., 2013) Sometimes when obtaining a family history, there is a 
lack of information secondary to adoption, loss of contact with relatives, deceased relatives, 
misdiagnosis, misinterpretation of medical information, or a lack of discussion about medical 
issues within the family. (Snider & Buckles, 2013) For these reasons, individuals with a 
negative family history should still be considered for genetic testing in some circumstances. 
(Goldman, 2005; 2012) Genetic testing would not change the course of treatment for a 
condition such as AD, but could confirm or suggest that a patient might be affected from an 
alternate form of dementia. This could inform relatives of a genetic risk and enable the 
proband to participate in research studies. (Snowden, Rollinson, & Thompson, 2012)  
Unlike other genetic testing clinics, relatives seeking predictive testing are almost 
entirely self-referred. As opposed to following the recommendation and order of a physician, 
the request for genetic testing is personally motivated. These individuals come in to identify 
and understand the possible contribution of genetic factors for a disease that appears to be 
part of their family history. NGS panels are able to cast a wider net per test for the avid 
information seeker. These patients are typically unaware of what distinguishes a genetic 
pattern for particular genes or the potential risks of testing— including chances for a VUS or 
inconclusive results. Still they are assumed to be vigilant and motivated to find an answer as 
they are self-referred and therefore, have demonstrated that drive. (Christensen, et al., 2015) 
Reasons for Predictive Testing   
Since dementias are typically progressive and currently have few treatments, 
management and long-term care planning can be beneficial.  (Hayden & Bombard, 2005) 
While any genetic testing may produce stress for an individual, testing for diseases with no 
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reliable preventive path or current cure can be especially psychologically complex. Research 
suggests that anxiety levels can be mitigated with proper protocols, such as seen with HD. 
(Garguilo, Lejeune, & Tanguy, 2009)  
Another cited reason for seeking presymptomatic testing is to alleviate uncertainty. 
Assuming the anxiety experienced by an individual seeking genetic testing is, to their mind, 
worse than the potential anxiety occasioned by a positive or uncertain result, is it ethical to 
deny testing?  Unexpected adverse events such as depression may follow a positive or 
uncertain result. While there is not, to date, a definitive answer on the balance of these risks, 
experts have pointed out that the risks are exacerbated when testing for dementias which are 
not preventable. (Molinuevo, et al., 2005) By way of comparison, most adult-onset cancer 
syndromes are associated with screening protocols and prophylactic measures. (Frost, et al., 
2004) 
Family members’ genetic testing results have also been identified as a predictor of 
psychological distress after testing. Post-test distress is highest when results differ between 
siblings, such as when one is a non-carrier and one is found to have BRCA1/2 mutation. 
(Loader, et al., 2001) Experience of a loss is another indicator of psychological distress post-
testing. Having a relative who died from breast or ovarian cancer causes many to perceive 
genetic testing as highly significant and reliable. (Thewes et al., 2003) Another study 
reported that being a member of a high-risk family was perceived as being more upsetting 
than the anticipation of receiving the result of genetic testing. (Coyne et al., 2003) Studies 
looking at the psychological effects of presymptomatic testing for HD have followed patients 
at varying ages over 6 months to 10 years. Each found a rate of approximately 17% of 
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patients experiencing adverse effects. These were predominately depression and 
psychological distress. (Lawson, et al., 1996)  
Approximately 6-8% of the general population has received genetic testing. (Blendon, 
Gorski, & Benson, 2016) A 2013 article by Henneman, et al. discusses an increase in 
awareness of genetic testing between the years 1990 and 2004, but suggests that it did not 
significantly increase between 2002 and 2010. The 2010 Wilde, et al. study showed positive 
attitudes toward genetic testing, mainly among those who have family histories of disease. In 
2001, Neumann et al. found that 79% of the general population in a telephone survey 
indicated that they were interested in predictive genetic testing for AD. Those who responded 
positively to this hypothetical decision cited the desire to spend time with family, sign 
advance directives, and purchase long-term care insurance if results were positive. 
The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study was 
designed to assess the impact of susceptibility testing on asymptomatic adult children of AD 
patients. (Roberts, et al, 2003) The strongest predictor of actual testing in this study was the 
pretest statement of desire to prepare one’s family for the possibility of developing AD. 
Findings also support prior research showing participants citing altruistic motivation for 
proceeding with genetic testing research. (Geller, et al, 1999) In this setting, it has been 
noted, kin altruism might be the more relevant term. (Batson, 1991) The motivation to 
increase the welfare of immediate family members clearly plays a part in the decision. It is 
also of interest to note that a small number of participants cited the use of genetic testing to 
plan for suicide if results were positive. Follow-up with this group suggested that each was 
only considering suicide as a viable alternative once they became symptomatic. Risk of 
suicide has played a more significant role in follow-up after genetic testing programs for 
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Huntington’s Disease. (Almqvist et al., 1999) It should be noted that  a predominant motive 
for choosing predictive HD testing remains to be a means to reduce ambiguity for the 
individual and his or her children as well as the ability to plan for long-term care. 
(Duisterhof, Trijsburg, Niermeijer, & Roos, 2001; Garguilo, Lejeune, & Tanguy, 2009) 
Impact of Testing 
Research studying the impact of predictive genetic testing for late-onset conditions on 
individuals is limited and has mainly focused on cancer and HD. The cancer studies focus on 
the clinical utility of the testing; that experience is notably different from dementia testing in 
that dementias are not currently preventable. Fewer studies have been published on genetic 
testing results associated with uncertain significance or results that were inconclusive. Frost 
et al. (2004) found women who received unclear variant information often expressed 
frustration and may have misinterpreted the results. Such a scenario highlights the 
importance of pre-testing counseling regarding the possibility of uncertain results. Croyle et 
al. (1995) determined that individuals with a high need for certainty may be particularly at 
risk for psychological distress when faced with uncertain, inconclusive, or delayed results.  
 Psychological impact of genetic testing is associated more closely with pre-test 
distress than testing results. (Reichelt et al., 2004) Many researchers suggest that because of 
the documented relationship between pre- and post-test anxiety, clinicians should identify 
those individuals with high levels of distress through formal assessment prior to genetic 
testing.  
Next Generation Sequencing 
Next Generation Sequencing (NGS) has revolutionized predictive and diagnostic 
medicine with the ability to sequence individual genes or the entire genome.  NGS tests have 
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been less effective at identifying deletions and duplications, however, labs are beginning to 
incorporate this option as part of NGS testing. Recent years have provided not only a 
remarkable improvement in sequencing technologies and capabilities, but also a reduction in 
the cost of testing. Based on information provided by the National Human Genome Research 
Institute at the NIH, the cost of sequencing a genome has fallen from approximately $500 
million to map the first human genome to approximately $1000. Further reductions can be 
expected in coming years as new platforms are brought to market. With lower costs on the 
horizon, genetic testing will be available to a wider range of the population.   
While there is a high potential efficacy of an NGS panel for hereditary dementias, this 
technology has been limited in its detection abilities. The inability to detect repeat mutations 
is particularly relevant, given their importance in this subset of genetic diseases. A separate 
test would need to be performed to pick up such mutations. Additionally, variants of 
unknown significance (VUS) remain a major limitation of NGS. The inconclusive result has 
the potential to leave the patient with more uncertainty than prior to testing, which they may 
wrongly interpret as positive or negative.  
The psychological impact of predictive Next Generation Sequencing panel testing for 
hereditary neurodegenerative disease on both affected and unaffected patients requires more 
study. Identifying the psychological side effects and attitudes will aid in the development of 
future protocols and may lead to normalization of dementia panels, and potentially easing 
accessibility for patients who desire the information.  
Unaffected patients are uniquely susceptible to a negative psychological impact 
resulting from genetic testing. While many initially describe the uncertainty of knowing 
whether they will develop the disease as being worse than a definitive positive response, they 
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cannot predict response to unknown outcomes. (Molinuevo, et al., 2005) They are often 
unaware of the potential of a VUS, or rare secondary panel findings, or of how they will react 
to receiving a positive result. (Semaka , Creighton, Warby , & Hayden, 2006) . Testing has 
the potential to have profound negative effects on the patient. It remains unclear whether the 
patient’s psychological posture is weakened after testing.   
Methods 
This study aims to document the psychological impact of panel testing for hereditary 
dementia on unaffected patients. The protocol for this study was developed by Karen Marder, 
MD and Jill Goldman, MPhil, MS, CGC of Columbia University Medical Center (CUMC). 
The main study is ongoing and will look at 30 participants over 6 months post-genetic testing 
results. This report functions as a pilot study covering a smaller sample over a shorter time 
frame.  
Participants 
Participants over the age of 18 were recruited and ascertained at CUMC via self-
referral for neurogenetic counseling. Participants were screened for candidacy over the phone 
by the genetic counselor. Accepted participants were categorized as either Control (having a 
known family mutation for a neurodegenerative disease), or Experimental (having a family 
history for disease without a known family mutation).  
Study Instruments 
The participants completed the following validated study instruments in the form of a 
questionnaire packet: Patient Health Questionnaire (PHQ-9), Generalized Anxiety (GAD-7), 
Brief COPE coping scale, Intolerance of Uncertainty (IUS), Modified Rumination-Reflection 
Questionnaire (mRRQ), Perceived Personal Control (PPC), Decision Regret Scale (DRS), 
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Attitudes Toward Genetic Research and Testing (ATT), Genetic Knowledge Questions 
(KNOW), and a Demographics questionnaire. These questionnaires were administered prior 
to the testing and the initial genetic counseling session, 1 months after receiving results, and 
6 months after receiving results. The DRS was only administered 1 month and 6 months after 
receiving results. For the purposes of this paper, the KNOW, ATT and 6 month 
questionnaires were not analyzed. This study is ongoing at CUMC and will be analyzed at a 
later point when more data is collected. 
Six months after receiving results, patients were asked to participate in a semi-
structured phone interview. Patients were asked to speak to their experience with genetic 
counseling and the presymptomatic testing protocol, the impact of the results, and the 
hypothetical situation in which the participant received the opposite result (Appendix).  
Data Collection 
Prior to the pre-test counseling appointment, informed consent and HIPAA forms 
were signed and then a questionnaire pack was completed by the participants. The genetic 
counseling session included a discussion of the symptoms, course, genetics, and the patient’s 
experience of the disease, reasons for testing, potential results, impacts of potential results, 
and insurance concerns. Participants underwent a neuropsychiatric evaluation by the 
neurologist following the genetic counseling session. Genetic testing eligibility was 
determined by the genetic counselor, who recommended either panel testing or single-gene 
testing. Genetic test results were given in person by the genetic counselor. Participants were 
required to bring a support person to this appointment. One month after receiving results, 
questionnaire packs were completed by the participants. Pre- and post-test questionnaires 
were compared using one-tailed t-tests. Experimental and Control questionnaires were 
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compared. Analysis was performed using SPSS software. P values 0.05 or lower are 
considered significant.  
The 6 month follow-up interviews were analyzed anecdotally due to the small sample 
size. This qualitative information was examined in the context of the observed qualitative 
trends.  
Genetic Testing 
All testing was performed at CUMC. The Control participants had targeted genetic 
testing for mutations previously identified in the family. The experimental group was tested 
using a custom panel determined by the genetic counselor. The Next Generation Sequencing 
panels were created from the following list of genes. Some but not all of these were included 
in every panel: 
PSEN1, PSEN2, APP, SOD1, ANG, TARDBP, FUS, VCP, ALS2, DCTN1, VAPB, SETX, 
SMN1, UBQLN2, MAPT, GRN, CHMP2B, APOE, LRRK2, GBA, PARK2, PINK1, SNCA, 
UCHL1, PRNP 
The panel also included repeat expansion mutation analysis in Intron 1 of C9orf72 using PCR 
and Southern blot analysis.   
IRB Approval 
This study received approval from the CUMC Institutional Review Board (Approval 
on February 11, 2016; Reapproved on November 15, 2016) and from the Sarah Lawrence 
College Institutional Review Board (Approval on September 26, 2016).  
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Results 
A total of 26 participants were recruited for the study by January 20, 2017; 15 were 
recruited for the control group and 8 for the experimental group. Table 1 lists the results for 
the demographic information collected.  The pre-counseling questionnaires were sent to all 
individuals, of which 23 continued in the study. To date, the one-month follow-up 
questionnaires were sent to 11 participants., and10 participants participated in the 6 month 
follow-up interview.  
The demographic information reflects a fair balance of gender and marriage status. 
Overall, the religious makeup of the participants is reflective of the New York Metropolitan 
area. Almost all participants who sought testing had completed a 4-year college. Over half of 
the participants had completed an advanced degree. Most participants were of Caucasian 
ethnicity.   
One experimental and two control participants did not continue far enough into the 
study to receive the blood draw for the genetic testing. Both of the control participants were 
at risk for HD. They had completed the initial genetic counseling session and psychiatric 
evaluation.  It was recommended by the psychiatrist that each see a therapist before receiving 
genetic testing.  The experimental patient halted her participation in the research after the 
initial genetic counseling session out of respect for her husband’s wishes to not pursue 
genetic testing for hereditary dementia. The data presented does not include information from 
the 3 participants who did not continue in the study. The data collected on the control group 
participants who withdrew contained outlier scores for anxiety. These two participants scored 
a 12 and 19 out of 21 (severe anxiety) for the pre-test GAD-7 (anxiety) scale versus the 
group average of 3.80. One of these participants had an outlying depression score at 17 out of 
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27 (severe depression) for the PHQ-9 compared to the group average of 4.33. The stopped 
experimental participant scored a 0 on both depression and anxiety scales. 
Of the control group participants, 4 received a positive test result and three received a 
negative result. Of the experimental group, all participants have received negative results. In 
both groups, no VUS’s were found.  
All participants had a family history of a neurodegenerative disease. Each had an 
affected family member within two degrees of separation. There was no significant 
difference between groups in the number of affected family members.   
To determine any difference in psychosocial effects between those with known 
family mutations and those without known family mutations, the pre and post testing scores 
were compared. First the pre and post testing scores were compared within each group and 
then between groups. 
The control group was not found to have any statistically significant findings among 
the psychological measures (Table 2a). Chief among the descriptive findings for the control 
group were decreases in depression and increases in anxiety and uncertainty. Similarly, the 
experimental group had only one statistically significant finding (Table 2b):  an observed 
decrease in the COPE Venting measure. On average, these participants were found to use 
venting as a coping mechanism significantly less after receiving test results.  Of note, an 
increase in perceived control was observed as well as decreases in positive reframing and 
planning as coping mechanisms. The decreases in usage of coping mechanisms may be 
reflective of the negative testing results received by each participant of the group. Overall, 
there were few statistically significant pieces of evidence in either group, which reflects the 
small sample sizes. 
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The experimental and control groups were similar on all but two of the 19 dependent 
variables studied.  The control group showed higher PPC scores both post and pre-test (Table 
3, Table 4), suggesting a higher level of control prior to the genetic counseling session. An 
evaluation of the background knowledge of the participants may be informative of this result. 
A higher level of control may be indicative of knowing a family mutation and being familiar 
with the inheritance and other aspects of the genetics pertaining to the family condition. The 
change in uncertainty for those with a known mutation was much higher than those with an 
unknown. Further exploration may reveal that this difference in uncertainty is connected to 
the ambiguity of disease onset for those in the control group who received positive results.  
For the other 17 outcome variables, the scores of the control group and experimental group 
did not show significant differences. This may indicate that any changes observed between 
pre and 1 month post test testing could be a response to genetic counseling instead of pre-
existing differences between the two groups.  Alternatively, any observed changes and 
reactions may reflect the varied personal experiences and context of each participant.    
Six Month Follow-Up Interviews 
 A six month follow-up was conducted. The eleven interviews included five subjects 
from the experimental group and six from the control group. There was consensus from all 
that that they did not regret the decision to test, nor would they have changed how each went 
about the process. One positive HD participant noted that a decision to wait longer may have 
been preferable. There remained a positive impression of genetic counseling and the 
presymptomatic process. Some were unhappy with the lack of patient autonomy inherent in 
the process imposed by the protocol as well as the length of time from beginning the protocol 
until receiving results. While some participants spoke of the psychiatric evaluation favorably, 
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others did not find this part of the process necessary.  A few reported being “treated like a 
patient” during this experience despite not being symptomatic.  
These interviews revealed a variety of reasons for testing. Planning for the future was 
an umbrella theme that included concern for securing the appropriate insurance and care, 
time management, especially as it relates to balancing family and work, financial 
considerations, and “buying that beach house,” as one participant noted. Cited less often as a 
reason for testing was the ability to know if the disease might be passed down to their 
children. Some of the subjects who received negative results in the experimental group with 
no known family mutation expressed relief tempered by the remaining uncertainty of a 
possible undiscovered genetic cause. This response helps explain the uncertainty noted in the 
quantitative results.  
 At this six month interview, almost all subjects testing negative reported that they 
were coping well, yet indicated that there remained the uncertainty of not knowing their 
genetic status. This mirrored the low level of anxiety measured throughout the process. The 
themes that emerged revolved around searching for knowledge. These included 
understanding one’s own genetic information, allowing the pursuit of research, participation 
in trials, and use of specialists should the result be positive. The majority indicated they 
would have paid for this testing if the cost was within reason. This statement was clarified to 
refer to a range of several thousand dollars.  
Further Control Group Analysis 
The control group data was further analyzed to shed light on the presymptomatic 
testing experience. Unlike the experimental group, these participants received a combination 
of positive and negative testing results (Table 6).  Of note, analysis of the 1 month follow-up 
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scores revealed a minimal mean increase in anxiety for the positive results group from pre-
test. Both the positive and negative participants exhibited decreases in depression after 
undergoing genetic testing, showing a trend toward positive mental effect from testing. The 
negative group showed a slightly larger decrease in depression than the positive group. 
Furthermore, the negative group showed a larger decrease in rumination after receiving test 
results whereas the positive group remained approximately stagnant.  
Further examination of the control group reveals a discrepancy between the 
participants at risk for HD versus other conditions. The separation of the HD data (both 
including and omitting the stopped participants) from the non-HD data showed increases in 
almost all scores among the HD patients, including anxiety and depression. A two-tailed t-
test revealed no statically significant variables. Of note, a larger increase in uncertainty 
(mean=8.08, t (10) = -.51, p=.67) was observed among the HD participants. The small 
sample size diminishes the accuracy of these values. This may be attributed to the uncertainty 
of onset among the HD-positive participants. The removal of the at-risk HD participants 
perhaps paints a more apt comparison to the experimental group due to the similar makeup of 
conditions within the families, given the more analogous experience with the nature and the 
genetics of the disease affecting their family.  
 
Discussion 
The aim of this study is to evaluate the differences in psychosocial effects between 
asymptomatic individuals with a known family mutation and those without. It was 
anticipated that there would be little difference between these two groups.  Since all 
participants without a known family mutation received negative testing results without any 
VUS’s or positive findings, the pilot data may not be adequate to draw conclusions drawn 
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about this population. Nearly all measures were found to be comparable between the groups 
pre-and post-test. No evidence was found to support increased negative psychosocial effects 
for those without a known family mutation in this pilot sample. The interviews reinforced 
favorable post-testing experiences. When looking at the interviews overall, this trend may be 
influenced by the higher proportion of negative results received overall. Reevaluation of 
these trends in a larger sample of participants may provide more definitive evidence of this 
trend.  
Overall, the patients evidenced little difficulty dealing with their experience of 
genetic testing. To date, there have not been any VUS results identified from testing, and 
participants did not report significant uncertainty. While the control group showed an 
increase in uncertainty over time and the experimental group indicated a small decrease, 
these differences between pre and post-testing were more extensive in the control group. This 
may be attributed to the positive results seen in this group. Further exploration into 
descriptive findings may conclude that residual uncertainty lingers with those who receive 
negative results in the absence of a known family mutation. If so, this may be due to the 
feeling that there is some lingering genetic risk that we are not as yet able to detect, even if 
the risk is minimized by a negative panel result. Uncertainty could remain with highly 
penetrant known mutations as well, since there are no effective tools available to predict 
exactly how and when the condition for which they are at risk will develop.  
Chief among the concerns about testing asymptomatic people was the possibility of 
significant increases in anxiety and depression, which were not observed in this pilot sample 
from either the questionnaires or the interviews. An examination of the associated scales 
found no difference in depression or anxiety between the experimental and control groups. 
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This may be attributed to the efficacy of the asymptomatic testing protocol.  What data we 
have support prior reports of the effectiveness of the protocol, and provide no evidence to 
suggest that testing in this population is an unethical or unsound practice.  
The qualitative information from the interviews is supportive of positive attitudes 
toward the presymptomatic protocol and interest in the availability of testing for hereditary 
dementia and associated neurodegenerative diseases. This anecdotal information is 
suggestive of a positive impact from the process of testing. Participants cited specific reasons 
for testing, most of which were intended to aid in alleviating uncertainty for their own futures 
and their families. Throughout the study, this knowledge-seeking motivation has been 
especially apparent in the experimental group. Discussions proved this group to be overall 
well-educated and exhibit similar personality traits, such as being planning and research 
oriented, or “type A.” This is congruent with what may be expected from a patient self-
referred for presymptomatic testing. In an effort to gain a better undertraining of those who 
seek predictive testing for neurodegenerative disease, tailored questionnaires specific to 
personality should be included in future studies.     
Study Limitations 
 The primary limitation of this study is the small sample size and lack of data from 
each participant. Notably, more interviews are needed for a more in depth analysis and to 
provide potentially important information about presymptomatic testing. This group may be 
uniquely reflective of the typical patient population at CUMC and further studies are 
encouraged to include a more diverse participant base. Moreover, the participants in the 
control group were predominantly at risk for HD. Control and experimental groups at risk for 
more similar conditions may allow for a more apt comparison.  
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Going forward, it is important to note that the questionnaire responses may be 
influenced by outside events during the testing process and results period. Two participants 
shared that during the time of the follow-up questionnaires, each was under high distress 
because of their respective parents’ worsening conditions. Additionally, there is an 
ascertainment bias with this study, in that all patient are self-referred. Therefore, there may 
be an initially higher level of anxiety and uncertainty in this population versus those who did 
not opt to participate.  
Conclusions and Future Directions 
The data thus far do not rule out either positive or neutral psychological outcomes of 
predictive genetic testing. The predictive testing protocol may be involved in mitigating 
negative effects when properly instituted, however, this cannot be proven in the absence of 
comparison data. Testing may mentally prepare participants and their loved ones for the 
future and allow them to take the necessary steps to secure care. Further studies are needed to 
assess the psychological states of those undergoing panel testing. This study will continue to 
attempt to understand the psychological impact of presymptomatic panel testing on the at-
risk population without a known family mutation. A larger study and more extensive 
longitudinal look at the effects on patients will help evaluate the lasting impact of the results 
and process of testing.  
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Variable Category N % 
Gender Male 6 40 
Female 9 60 
Age Range  18-29 4 26.67 
30-39 7 46.67 
40-49 1 6.67 
50-59 2 13.33 
60-69 1 6.67 
Marriage 
Status 
Married 8 53.33 
Single 7 46.67 
Education High School 0 0 
4 Year 
College 
5 33.33 
Advanced 
Degree 
9 60 
Ethnicity  African 
American/ 
Black 
1 6.67 
Asian 1 6.67 
White/ 
Caucasian 
12 80 
Mixed 
Ethnicity 
1 6.67 
Religion  Catholic 3 20 
Protestant  1 6.67 
Muslim 1 6.67 
Jewish 5 3.33 
Mixed 0 0 
None 1 6.67 
Other 2 13.33 
Indication  HD 9 60 
ALS 3 20 
CJD 1 6.67 
FTD 2 13.33 
Appendix 1: Tables 
Variable Category N % 
Gender Male 4 50 
Female 4 50 
Age Range  18-29 0 0 
30-39 5 62.5 
40-49 2 25 
50-59 1 12.5 
60-69 0 0 
Marriage 
Status 
Married 5 62.5 
Single 3 37.5 
Education High School 0 0 
4 Year College 2 25 
Advanced 
Degree 
6 75 
Ethnicity  African 
American/ 
Black 
0 0 
Asian 0 0 
White/ 
Caucasian 
7 87.5 
Mixed 
Ethnicity 
1 12.5 
Religion  Catholic 1 12.5 
Protestant  2 25 
Muslim 1 12.5 
Jewish 0 0 
Mixed 1 12.5 
None 3 37.5 
Other 0 0 
Indication  AD 4 50 
FTD/ALS 1 12.5 
AD/FTD 3 37.5 
 
Table 1a. Sociodemographic 
Variables: Control Group 
 
   
  Table 1b. Sociodemographic Variables:    
  Experimental Group 
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Table 2a: Control Group Score Differences Between Pre-Test and One Month Follow-
up 
 PRE-TEST 
MEAN (N=15) 
1 MO. 
FOLLOW-
UP MEAN 
(N=7) 
MEAN 
DIFFERENCE 
T P LEVEL* 
GAD-7 
ANXIETY 
2.71 4.14 +1.42 -1.18 0.14 
PHQ-9 
DEPRESSION 
4.43 3.14 -1.29 1.49 0.09 
PPC 
CONTROL 
15.57 15.86 -0.29 -0.26 0.40 
MRRQ 
RUMINATION 
26.57 25.14 -1.43 0.61 0.28 
IUS 
UNCERTAINTY 
45.14 52.71 +7.57 1.07 0.16 
COPE SELF-
DISTRACTION 
4.43 3.57 -0.86 1.16 0.14 
COPE ACTIVE COPING 5.29 4.29 -1.00 1.08 0.16 
COPE DENIAL 2.00 2.57 -0.57 -1.33 0.11 
COPE SUBSTANCE USE 2.43 2.00 -0.43 1.00 0.18 
COPE EMOTIONAL 
SUPPORT 
5.00 4.43 -0.57 1.00 0.18 
COPE INSTRUMENTAL 
SUPPORT 
4.00 4.57 +0.57 -0.93 0.18 
COPE BEHAVIORAL 
DISENGAGEMENT  
2.29 2.86 +0.57 -1.08 0.16 
COPE VENTING 4.14 4.43 -0.29 -0.33 0.37 
COPE POSITIVE 
REFRAMING 
3.43 4.71 +1.28 -1.59 0.08 
COPE PLANNING 5.86 5.00 -0.86 0.78 0.23 
COPE HUMOR 3.14 4.14 +1.00 -1.73 0.06 
COPE ACCEPTANCE 6.00 6.43 +0.43 -0.37 0.36 
COPE RELIGION**      
COPE SELF BLAME 2.14 2.14 0.00 0.00 1.00 
*for one-tailed test 
**Religion could not be computed as the scores were the same with 0 standard deviations 
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Table 2b: Experimental Group Score Differences Between Pre-Test and One Month 
Follow-up 
 PRE-TEST 
MEAN (N=8) 
1 MO. 
FOLLOW-
UP MEAN 
(N=4) 
MEAN 
DIFFERENCE 
T P LEVEL* 
GAD-7 
ANXIETY 
2.50 2.50 0.00 0.00 1.00 
PHQ-9 
DEPRESSION 
1.50 1.50 0.00 0.00 1.00 
PPC 
CONTROL 
9.50 11.50 +2.00 -0.59 0.30 
MRRQ 
RUMINATION 
27.25 25.25 -1.75 1.48 0.12 
IUS 
UNCERTAINTY 
46.50 46.25 -0.25 0.05 0.48 
COPE SELF-
DISTRACTION 
4.00 3.25 -0.75 1.00 0.19 
COPE ACTIVE COPING 4.50 4.00 -0.50 1.00 0.19 
COPE DENIAL 2.25 2.00 -0.25 1.00 0.19 
COPE SUBSTANCE USE 2.00 2.00 0.00 0.00 1.00 
COPE EMOTIONAL 
SUPPORT 
4.25 3.50 -0.75 1.56 0.15 
COPE INSTRUMENTAL 
SUPPORT 
3.50 3.00 -0.50 1.00 0.19 
COPE BEHAVIORAL 
DISENGAGEMENT 
2.50 2.00 -0.50 1.00 0.19 
COPE VENTING 3.50 2.50 -1.00 2.45 0.04 
COPE POSITIVE 
REFRAMING 
5.00 3.75 -1.25 1.67 0.09 
COPE PLANNING 5.86 5.00 -0.86 0.78 0.23 
COPE HUMOR 3.25 3.00 -0.25 1.00 0.19 
COPE ACCEPTANCE 5.50 4.75 -0.75 1.57 0.15 
COPE RELIGION**      
COPE SELF BLAME 2.25 2.50 +0.25 -1.00 0.19 
*for one-tailed test 
**Religion could not be computed as the scores were the same with 0 standard deviations 
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Table 3a: Pre-Test Score Differences Between Control and Experimental Groups 
 
 CONTROL 
MEAN 
(N=15) 
EXP 
MEAN 
(N=8) 
MEAN 
DIFFERENCE 
T P LEVEL* 
GAD-7 
ANXIETY 
3.80 2.13 -1.67 1.53 0.14 
PHQ-9 
DEPRESSION 
4.33 1.88 -2.45 1.88 0.08 
PPC 
CONTROL 
14.60 11.00 -3.60 2.84 0.01 
MRRQ 
RUMINATION 
27.67 25.13 -2.54 0.68 0.50 
IUS 
UNCERTAINTY 
47.13 39.88 -7.25 1.26 0.22 
COPE SELF-
DISTRACTION 
4.07 4.00 -0.07 0.11 0.91 
COPE ACTIVE COPING 5.27 4.75 -0.57 0.58 0.58 
COPE DENIAL 2.20 2.13 -0.07 0.26 0.75 
COPE SUBSTANCE USE 2.20 2.00 -0.20 0.77 0.48 
COPE EMOTIONAL 
SUPPORT 
5.33 5.13 -0.20 0.30 0.77 
COPE INSTRUMENTAL 
SUPPORT 
4.07 4.50 +0.43 -0.57 0.57 
COPE BEHAVIORAL 
DISENGAGEMENT  
2.33 2.25 -0.08 0.29  0.77 
COPE VENTING 3.87 3.38 -0.49 0.73 0.47 
COPE POSITIVE 
REFRAMING 
4.07 4.88 +0.81 -1.04 0.31 
COPE PLANNING 6.07 5.63 -0.44 0.74 0.47 
COPE HUMOR 3.07 2.75 -0.32 0.52 0.61 
COPE ACCEPTANCE 5.60 5.88 +0.28 -0.39 0.70 
COPE RELIGION 3.87 4.13 +0.26 -0.24 0.82 
COPE SELF BLAME 2.27 2.13 0.14 0.62 0.54 
*For one-tailed test 
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Table 3b: One Month Follow-up Score Differences Between Control and Experimental 
Groups 
 
 CONTROL 
MEAN (N=7) 
EXP 
MEAN 
(N=4) 
MEAN 
DIFFERENCE 
T P LEVEL* 
GAD-7 
ANXIETY 
4.14 2.50 -1.64 0.73 0.48 
PHQ-9 
DEPRESSION 
3.14 1.50 -1.64 0.53 0.17 
PPC 
CONTROL 
15.68 11.50 -4.36 2.65 0.03 
MRRQ 
RUMINATION 
25.14 25.50 0.36 -0.06 0.96 
IUS 
UNCERTAINTY 
52.71 46.25 -6.46 0.57 0.58 
COPE SELF-
DISTRACTION 
3.57 3.25 -0.32 0.31 0.76 
COPE ACTIVE 
COPING 
4.29 4.00 -0.29 0.24 0.82 
COPE DENIAL 2.57 2.00 -0.57 0.98 0.35 
COPE SUBSTANCE 
USE 
2.00 2.00 0.00 ** ** 
COPE EMOTIONAL 
SUPPORT 
4.43 3.50 -0.93 0.93 0.37 
COPE 
INSTRUMENTAL 
SUPPORT 
4.57 3.00 -1.57 1.16 0.27 
COPE BEHAVIORAL 
DISENGAGEMENT  
2.86 2.00 -0.86 1.44 0.20 
COPE VENTING 4.43 2.50 -1.93 1.86 0.10 
COPE POSITIVE 
REFRAMING 
4.71 3.75 -0.96 0.64 0.54 
COPE PLANNING 5.00 4.00 -1.00 -0.69 0.51 
COPE HUMOR 4.14 3.00 -1.14 0.90 0.39 
COPE ACCEPTANCE 6.43 4.75 -1.68 1.37 0.20 
COPE RELIGION 2.86 3.50 +0.64 -0.41 0.70 
COPE SELF BLAME 2.14 2.50 +0.36 -0.87 0.41 
*For one-tailed test                  
**could not be computed because S.D.=0 
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Table 4: Comparison of Score Differences from Pre-Test and One Month Follow-
up Between Control and Experimental Groups 
 
CONTROL 
MEAN  
(N=7) 
 
MEAN 
DIFFERENCE T P LEVEL* 
EXPERIMENTAL 
MEAN 
(N=7) 
 
GAD-7 
-1.42 0 -1.42 -0.82 0.43 
ANXIETY 
PHQ-9 
1.28 0 1.28 1.06 0.32 
DEPRESSION 
PPC 
-0.28 -2 1.71 0.59 0.57 
CONTROL 
MRRQ 
1.43 1.75 -0.32 -0.1 0.9 
RUMINATION 
IUS 
-7.75 0.25 -7.82 -0.77 0.46 
UNCERTAINTY 
COPE SELF-
DISTRACTION 0.86 0.75 0.11 0.09 0.93 
COPE ACTIVE COPING 1 0.5 0.5 0.38 0.71 
COPE DENIAL -0.57 0.25 -0.82 -1.35 0.21 
COPE SUBSTANCE USE 0.43 0 0.43 0.74 0.48 
COPE EMOTIONAL 
SUPPORT 0.57 0.75 -0.18 -0.21 0.84 
COPE INSTRUMENTAL 
SUPPORT -0.57 0.5 -1.07 -1.18 0.27 
COPE BEHAVIORAL 
DISENGAGEMENT  -0.57 0.5 -1.07 -1.34 0.21 
COPE VENTING -0.29 1 -1.28 -1.06 0.32 
COPE POSITIVE 
REFRAMING 8.14 8.75 -0.61 -0.24 0.81 
COPE PLANNING 0.86 1.5 -0.64 -0.41 0.69 
COPE HUMOR -1 0.25 -1.25 -1.56 0.15 
COPE ACCEPTANCE -0.43 0.75 -1.17 -0.73 0.87 
COPE RELIGION 0 0 0 0 1 
COPE SELF BLAME 0 0 0 0 1 
*For one-tailed test    
Negative values denote an increase in score for Table 4.          
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Table 5: Comparison of Control Group 1 Month Follow-up Scores: Positive versus 
Negative Testing Results 
 
 POSITIVE MEAN 
(N=3) 
NEGATIVE 
MEAN (N=4) 
MEAN DIFFERENCE 
GAD-7 
ANXIETY 
4.33 4.00 0.33 
PHQ-9 
DEPRESSION 
3.66 2.75 0.91 
PPC 
CONTROL 
17.00 15.00 2.00 
MRRQ 
RUMINATION 
25.67 24.75 0.92 
IUS 
UNCERTAINTY 
53.33 52.25 1.08 
COPE SELF-DISTRACTION 3.67 3.50 0.17 
COPE ACTIVE COPING 4.33 4.25 0.08 
COPE DENIAL 2.00 3.00 1.00 
COPE SUBSTANCE USE 2.00 2.00 0.00 
COPE EMOTIONAL SUPPORT 5.33 3.75 1.58 
COPE INSTRUMENTAL 
SUPPORT 
4.00 5.00 1.00 
COPE BEHAVIORAL 
DISENGAGEMENT  
3.33 2.50 0.83 
COPE VENTING 4.00 4.75 0.75 
COPE POSITIVE REFRAMING 6.33 3.50 2.83 
COPE PLANNING 5.67 4.50 1.17 
COPE HUMOR 5.33 3.25 2.08 
COPE ACCEPTANCE 7.33 5.75 1.58 
COPE RELIGION 2.00 3.50 1.50 
COPE SELF BLAME 2.00 2.25 0.25 
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Table 6: Comparison of Control Group HD and Non-HD  
 
 PRE-
TEST HD 
MEAN 
(N=9) 
1 MO. 
FOLLOW-
UP HD 
MEAN 
(N=3) 
MEAN 
DIFFERENCE 
HD PRE TO 1 
MO. 
FOLLOW-UP 
 
MEAN 
DIFFERENCE 
NON-HD PRE 
TO 1 MO. 
FOLLOW-UP 
 
PRE-
TEST 
NON-
HD 
MEAN 
(N=6) 
1 MO. 
FOLLOW-UP 
NON-HD 
MEAN 
(N=4) 
GAD-7 
ANXIETY 
4.63 4.33 -0.3 1.33 2.67 4.00 
PHQ-9 
DEPRESSION 
6.13 4.00 -2.13 -0.33 2.33 2.00 
PPC 
CONTROL 
14.63 17.00 2.37 --0.5 14.50 15.00 
MRRQ 
RUMINATION 
31.13 30.67 -0.46 -3.5 24.50 21.00 
IUS 
UNCERTAINTY 
48.25 56.33 8.08 3.67 46.33 50.00 
COPE SELF-
DISTRACTION 
4.63 4.67 0.04 -0.42 3.17 2.75 
COPE ACTIVE 
COPING 
5.88 4.00 -1.88 0.17 4.33 4.50 
COPE DENIAL 2.00 2.00 0 --0.5 2.50 3.00 
COPE SUBSTANCE 
USE 
2.38 2.00 -0.38 0 2.00 2.00 
COPE EMOTIONAL 
SUPPORT 
5.54 6.00 0.46 -1.25 4.50 3.25 
COPE 
INSTRUMENTAL 
SUPPORT 
4.64 6.00 1.36 0.33 3.17 3.50 
COPE BEHAVIORAL 
DISENGAGEMENT  
2.28 3.33 1.05 0.17 2.33 2.50 
COPE VENTING 4.00 5.33 1.33 0.25 3.50 3.75 
COPE POSITIVE 
REFRAMING 
4.63 6.33 1.7 0.17 3.33 3.50 
COPE PLANNING 6.13 5.33 -0.8 -1.25 6.00 4.75 
COPE HUMOR 3.13 4.67 1.54 0.58 3.17 3.75 
COPE ACCEPTANCE 5.25 7.33 2.08 -0.25 6.00 5.75 
COPE RELIGION 4.13 4.00 -0.13 -1.67 3.67 2.00 
COPE SELF BLAME 2.25 2.33 0.08 -0.33 2.33 2.00 
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Appendix 2: Six Month Follow-up Interview  
Developed by Jill Goldman, MPhil, MS, CGC 
 
 
Introduction: In this interview, we will be asking you about your experience with genetic 
counseling and testing. First we will address your reactions to your actual results, then we 
will ask you some hypothetical questions, then we will ask you for suggestions about the 
counseling and testing process, and finally a few demographic questions. 
As you remember, you were tested for _____ through (a single gene test) (a panel of gene 
tests). Your results indicated that you (carry) (do not carry) (have a result of unknown 
significance in) the gene(s) ( ) that cause(s) ______. Now I would like to ask you some 
questions about this about this testing and result. 
 
1.   Now that you are 6-months out from receiving test results, how do you feel about 
your decision to do genetic testing for the disease in your family? 
 
2.   How did you feel while going through the predictive testing protocol (genetic testing 
and neuropsychiatric evaluation)? 
 
3.   Have you or another family member previously experienced genetic counseling 
and/or testing? If so, how did this experience compare? 
 
4.   After being counseled about possible results of unknown significance (an 
uninterpretable result), what kind of concerns did you have, if any? 
 
5.   If you received a result of unknown significance, how are you dealing with the 
uncertainty? 
 
6.   Talk about anything we discussed during the genetic counseling session that made 
you think about your situation differently than when you called for your appointment 
or anything you reflected on afterwards. 
 
7.   How did you first react upon receiving results? 
 
8.   With whom (spouse/partner, children, siblings, friends, employer) did you share 
results and how did they react?  Did you talk about your testing before getting results 
or only after?  
 
9.   How do you feel that you are coping with the results now (any anxiety, depression)? 
 
10.  If you received any results of unknown significance, how are (would) you dealing 
with the uncertainty? 
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11.  How will the result affect your everyday life? 
 
12.  How will the result effect your future? 
 
13.  How will the result affect your use of the healthcare system or medications? 
 
Now we will ask you some what if questions about having received the opposite result or a 
result of unknown significance. 
14.  If you had received the opposite result (state negative or positive), how would it have 
affected your everyday life? 
 
15.  If you had received the opposite result (state negative or positive), how would it have 
affected your future? 
 
16.  If you had received the opposite result (state negative or positive), how would it have 
affected your use of the healthcare system or medications? 
 
17.  If you had received a result of unknown significance, do you think you would be able 
to deal with the uncertainty? Why? 
 
Now we are going to ask you about your experience with the research and the predictive 
counseling process. 
18.  If you were starting the process all over, would you do anything differently? For 
example, would you have chosen to enter this research project or instead go through 
clinically testing without the research? Would you have chosen to go to a doctor who 
would have tested you without genetic counseling? 
 
19.  We asked you to think about obtaining life and long-term care insurance prior to 
testing. Did you do so? How did it make you feel to have to think about future care? 
 
20.  Do you feel that your decision to be tested was influenced by the fact that it was free 
if you participated in this research? Would you have tested if you had to pay for it out 
of pocket? 
21.  What suggestions would you make to improve the process of predictive testing?  
